[Adrenergic betablockers and heart failure].
Several studies have shown that beta-blockade could provide functional benefit in heart failure, suggesting a deleterious role for the compensatory sympathetic stimulation. Betablockers induced benefit could result from either antagonism of myocardial beta-adrenergic stimulation or, on the contrary a paradoxical increased cardiac beta-adrenergic responsiveness secondary to beta-adrenergic receptor up-regulation. Two recently completed large scale multicentric placebo controlled studies, the MDC trial with metoprolol and CIBIS with bisoprolol, have confirmed that beta-blockade could functionally improve patients with heart failure. The observed survival improvement in non-ischaemic patients was observed only in the CIBIS trial. This result requires confirmation by additional studies.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D017298:Bisoprolol / Q000627:therapeutic use; D002311:Cardiomyopathy, Dilated / Q000150:complications; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008790:Metoprolol / Q000627:therapeutic use; D016019:Survival Analysis; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000503:physiopathology; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D008790:Metoprolol; D017298:Bisoprolol
Bêtabloquants adrénergiques et insuffisance cardiaque.